Pneumagen to present on further significant development for its lead product, Neumifil at BioTrinity 2022

St Andrews, UK – 13 April 2022 – Pneumagen, a clinical stage pharmaceutical company developing Neumifil, a first in class pan-antiviral for the prevention, treatment and management of viral induced respiratory infections is pleased to announce that its CEO, Douglas Thomson, will present at this year’s BioTrinity during a session focused on scientific updates in Infectious Diseases.

Presentation details

Date: Wednesday, 27th April 2022

Time: 15:10pm BST

Location: 155 Bishopsgate, London

Douglas Thomson will provide an overview of the company and the clinical advancement of its lead, self-administered intranasal product Neumifil, being developed for the treatment of a broad range of viral respiratory tract infections such as influenza, respiratory syncytial virus (RSV) and coronaviruses including SARS-CoV-2. Neumifil is currently in a Phase 1 clinical trial with top line results expected in the first half of 2022.

END

About Pneumagen

Pneumagen is a clinical- stage biotech company developing Neumifil, its lead product, as an intranasal drug for the prophylaxis and treatment of a broad range of viral respiratory tract infections (RTIs).

Neumifil is a novel, engineered multivalent Carbohydrate Binding Molecule (mCBM), which is being developed for the universal treatment of Influenza Virus (IFV), Respiratory Syncytial Virus (RSV), and coronavirus infections including COVID-19. Neumifil acts by directly binding and preventing the entry of the viral pathogens into the lungs with reduced susceptibility to direct viral resistance. Neumifil was generated using Pneumagen’s proprietary GlycoTarge™ technology that acts by stopping viruses at the site of infection, reducing their ability both to enter cells and to migrate to the lungs.

In addition to Neumifil, Pneumagen is harnessing its GlycoTarge™ platform to enable the development of a pipeline of intranasal therapies targeting other infectious lung diseases.

Pneumagen was established in 2016 as a spin-out from the University of St Andrews in Scotland giving Pneumagen access to world-class scientific expertise and capabilities in viral RTI’s specifically related to glycobiology.

For further information, please contact:

Pneumagen                                                                                       

Douglas Thomson, CEO

Email: info@pneumagen.com

MEDiSTRAVA Consulting (Financial PR)

Frazer Hall, David Dible, Sandi Greenwood, Evelyn McCormack

Email: Pneumagen@medistrava.com